DOCSLIB.ORG

Concentrations of Prostaglandin Endoperoxide Synthase and Prostaglandin I2 Synthase in the Endothelium and Smooth Muscle of Bovine Aorta

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Concentrations of Prostaglandin Endoperoxide Synthase and Prostaglandin I2 Synthase in the Endothelium and Smooth Muscle of Bovine Aorta Concentrations of prostaglandin endoperoxide synthase and prostaglandin I2 synthase in the endothelium and smooth muscle of bovine aorta. D L DeWitt, … , W K Sonnenburg, W L Smith J Clin Invest. 1983;72(6):1882-1888. https://doi.org/10.1172/JCI111151. Research Article Platelets adhere to the subendothelial layer of newly deendothelialized arteries. Attachment can be reduced with exogenous prostacyclin (PGI2). Thus, the subendothelium may be unable to produce sufficient PGI2 to prevent platelet adherence and subsequent platelet-platelet interaction. Consistent with this explanation are data from an earlier report (1977. Moncada S., A. G. Herman, E. A. Higgs, and J. R. Vane. Thromb. Res. 11:323-344) indicating that the smooth muscle layer of aorta has only 10-15% of the capacity of endothelial cells to synthesize PGI2. We have measured the concentrations of PGI2 synthase and prostaglandin endoperoxide (PGH) synthase in bovine aorta and obtained results quite different from those described in this earlier report. Tandem immunoradiometric assays for PGI2 synthase and PGH synthase antigens were used to quantitate these proteins in detergent-solubilized homogenates of endothelial cells and smooth muscle tissue prepared from 10 different bovine aorta. The concentrations of PGI2 synthase in endothelial cells and smooth muscle were found to be the same. However, the concentration of PGH synthase in endothelial cells averaged greater than 20 times that of smooth muscle. Results similar to those determined by immunoradiometric assay were also obtained when PGH synthase and PGI2 synthase catalytic activities were measured in preparations of endothelial and smooth muscle cells. Furthermore, when bovine aorta and renal arteries were subjected to immunocytofluorescence staining using monoclonal […] Find the latest version: https://jci.me/111151/pdf Concentrations of Prostaglandin Endoperoxide Synthase and Prostaglandin I2 Synthase in the Endothelium and Smooth Muscle of Bovine Aorta DAVID L. DEWITT, JEFFREY S. DAY, WILLIAM K. SONNENBURG, and WILLIAM L. SMITH, Department of Biochemistry, Michigan State University, East Lansing, Michigan 48824 A B S T R A C T Platelets adhere to the subendothelial fluorescence staining of equivalent intensity was de- layer of newly deendothelialized arteries. Attachment tected in both the endothelial cells and the smooth can be reduced with exogenous prostacyclin (PGI2). muscle. Moreover, the intensity of fluorescence was Thus, the subendothelium may be unable to produce similar throughout cross-sections of vascular smooth sufficient PGI2 to prevent platelet adherence and sub- muscle, indicating that there is no gradient in PGI2 sequent platelet-platelet interaction. Consistent with synthase concentrations between the endothelium and this explanation are data from an earlier report (1977. adventitia. Our results indicate that the propensity of Moncada S., A. G. Herman, E. A. Higgs, and J. R. platelets to adhere to the subendothelium of deen- Vane. Thromb. Res. 11:323-344) indicating that the dothelialized arteries and form aggregates cannot be smooth muscle layer of aorta has only 10-15% of the attributed simply to an inability of the denuded vas- capacity of endothelial cells to synthesize PGI2. We culature to produce PGI2 from PGH2, but may be a have measured the concentrations of PGI2 synthase and consequence of the low PGH synthase activity of smooth prostaglandin endoperoxide (PGH) synthase in bovine muscle. Consistent with this concept are the results of aorta and obtained results quite different from those Eldor et al. (1981. J. Clin. Invest. 67:735-741) who described in this earlier report. Tandem immunora- reported that increases in PGH synthase activity are diometric assays for PGI2 synthase and PGH synthase associated with formation of a nonthrombogenic neoin- antigens were used to quantitate these proteins in de- tima. tergent-solubilized homogenates of endothelial cells and smooth muscle tissue prepared from 10 different bovine INTRODUCTION aorta. The concentrations of PGI2 synthase in endo- thelial cells and smooth muscle were found to be the Prostaglandin I2 (prostacyclin, PGI2)1 is a potent va- same. However, the concentration of PGH synthase in sodilator and antithrombogenic agent (1-3) formed endothelial cells averaged >20 times that of smooth from the prostaglandin endoperoxide PGH2 through muscle. Results similar to those determined by im- the action of prostacyclin synthase (4-6). Early studies munoradiometric assay were also obtained when PGH on rabbit aorta indicated that the endothelium was the synthase and PGI2 synthase catalytic activities were major site of vascular PGI2 synthesis and that smooth measured in preparations of endothelial and smooth muscle had considerably less prostacyclin synthase ac- muscle cells. Furthermore, when bovine aorta and renal tivity than endothelial cells (7). These results formed arteries were subjected to immunocytofluorescence the basis for the hypothesis that adherence of platelets staining using monoclonal antibodies to PGI2 synthase, to the vascular subendothelium resulted from a rela- tive inability of vascular smooth muscle to synthesize During the time this work was performed Dr. David L. DeWitt was the recipient of U.S. Public Health Service Traineeship HL07404. Dr. William L. Smith is an Established I Abbreviations used in this paper: BAE cells, bovine aor- Investigator of the American Heart Association. Address all tic endothelial cells; DMEM, Dulbecco's-modified Eagle's correspondence to Dr. Smith. medium; IRA, immunoradiometric assay; PGH synthase, Received for publication 31 March 1983 and in revised prostaglandin endoperoxide synthase; PGI2 synthase, pros- form 9 August 1983. taglandin I2 (prostacyclin) synthase. 1882 J. Clin. Invest. © The American Society for Clinical Investigation, Inc. - 0021-9738/83/12/1882/07 $1.00 Volume 72 December 1983 1882-1888 PGI2 from PGH2 (2, 7). It is now clear, however, that bovine serum was used to dislodge the cells. Aliquots (0.5 ml) of the cell suspension were then applied to sterile glass arterial smooth muscle cells (8-11) cultured from a coverslips placed in 100 X 20-mm culture dishes (Corning variety of sources are capable of synthesizing PGI2 Glass Works, Corning Medical and Scientific, Corning, NY) from PGH2 at rates comparable to those obtained with and cells allowed to adhere overnight at 370C under a H20- cultured endothelial cells (10, 11). saturated 10% CO2 atmosphere. The coverslips were then We recently prepared monoclonal antibodies to washed once with Krebs buffer, pH 7.4, quick-frozen in pen- tane (-70'C) and dried. The cells were then subjected to PGI2 synthase (6). In using these reagents to determine indirect immunocytofluorescence staining for Factor VIII the subcellular location of this enzyme by immuno- antigen (14) and examined under a Leitz Orthoplan fluo- cytochemistry (12), we noted that the intensity of PGI2 rescence microscope (E. Leitz, Inc., Rockleigh, NJ). In ex- synthase-positive immunofluorescence was similar in amining cells from three separate isolates, we found that both the endothelial cells and the underlying smooth >99% of the cells examined in random fields stained for Factor VIII. This indicates that our BAE cell isolates were muscle. This observation, coupled with previous evi- essentially pure endothelial cell populations. dence for efficient PGI2 synthesis by cultured smooth Preparation of solubilized endothelial cell homogenates. muscle cells (8-11), led us to quantitate PGI2 synthase For assays of PGH synthase, BAE cells (<100 mg wet wt) in fresh vascular smooth muscle and endothelial cell isolated from single aorta were thawed and then homoge- extracts a newly developed immunoradiometric nized using a glass homogenizer in 0.5 ml of 0.1 M Tris- using chloride, pH 8.0 containing 2.5 mM diethyldithiocarbamate, assay (IRA) for this protein. In contrast to the results 5 mM EDTA, and 1% Tween 20. The sample was allowed obtained by Moncada et al. (7), our data indicate that to stand at 40C for 30 min. The solubilized BAE cell ho- the concentration of PGI2 synthase is the same in dif- mogenate was used to assay (a) PGH synthase antigen by ferent layers of the vasculature; however, the results IRA or (b) cyclooxygenase activity using the radioisotope assay described below. of parallel studies quantitating PGH synthase indicate For assays of PGI2 synthase, the isolated BAE cells were that this enzyme is present in considerably higher con- homogenized and solubilized in 0.5 ml of 0.1 M Tris-chloride centrations in endothelial cells than in smooth muscle. containing 10' M Flurbiprofen and 0.5% Triton X-100. This sample was used for both IRA and the enzyme activity assay. Preparation of solubilized smooth muscle homogenates. METHODS After removal of the endothelium, the smooth muscle was Materials. Diethyldithiocarbamate and Tween 20 were cut into 2-cm8 pieces and stored at -80'C. Before assay, obtained from Sigma Chemical Co. (St. Louis, MO) Dul- tissue (5 g) was cut into slivers and homogenized in 5 vol of becco's-modified Eagle's medium (DMEM), antibiotic-an- either (a) 0.1 M Tris-chloride, pH 8.0 containing 2.5 mM timycotic (1OOX), and fetal bovine serum were all purchased diethyldithiocarbamate and 5 mM EDTA (PGH synthase) or from Gibco Laboratories (Grand Island, NY). Collagenase (b) 0.1 M Tris-chloride, pH 8.0 containing 10' M Flurbi- (CLS II) was from Worthington Biochemical Corp. (Freehold, profen (PGI2 synthase) using a homogenizer (Polytron, NJ). [5,6,8,9,11,12,14,15-8H]Arachidonic acid (100 Ci/mmol) Brinkmann Instruments, Inc., Westbury, NY). The crude ho- and Na'"I (100 m Ci/ml) were products of New England mogenate was filtered through one layer of cheesecloth. The Nuclear (Boston, MA). Triton X-100 and rabbit anti-human fibrous matter that did not pass through the cheesecloth was Factor VIII serum were from Calbiochem-Behring Corp., resuspended in 5 vol of homogenizing buffer, rehomogenized, American Hoechst Corp. (San Diego, CA). Flurbiprofen was and refiltered as before. The two filtrates were combined and generously supplied by Dr. Udo Axen of the Upjohn Co.
Load more

Recommended publications
  • Endogenous Biosynthesis of Prostacyclin and Thromboxane and Platelet Function During Chronic Administration of Aspirin in Man
    Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. G A FitzGerald, … , J A Lawson, A R Brash J Clin Invest. 1983;71(3):676-688. https://doi.org/10.1172/JCI110814. Research Article To assess the pharmacologic effects of aspirin on endogenous prostacyclin and thromboxane biosynthesis, 2,3-dinor-6- keto PGF1 alpha (PGI-M) and 2,3-dinor-thromboxane B2 (Tx-M) were measured in urine by mass spectrometry during continuing administration of aspirin. To define the relationship of aspirin intake to endogenous prostacyclin biosynthesis, sequential urines were initially collected in individuals prior to, during, and subsequent to administration of aspirin. Despite inter- and intra-individual variations, PGI-M excretion was significantly reduced by aspirin. However, full mass spectral identification confirmed continuing prostacyclin biosynthesis during aspirin therapy. Recovery of prostacyclin biosynthesis was incomplete 5 d after drug administration was discontinued. To relate aspirin intake to indices of thromboxane biosynthesis and platelet function, volunteers received 20 mg aspirin daily followed by 2,600 mg aspirin daily, each dose for 7 d in sequential weeks. Increasing aspirin dosage inhibited Tx-M excretion from 70 to 98% of pretreatment control values; platelet TxB2 formation from 4.9 to 0.5% and further inhibited platelet function. An extended study was performed to relate aspirin intake to both thromboxane and prostacyclin generation over a wide range of doses. Aspirin, in the range of 20 to 325 mg/d, resulted in a dose-dependent decline in both Tx-M and PGI-M excretion. At doses of 325-2,600 mg/d Tx-M excretion ranged from 5 to 3% of control values while PGI-M remained at 37-23% of control.
    [Show full text]
  • Challenging the FDA Black Box Warning for High Aspirin Dose with Ticagrelor in Patients with Diabetes James J
    PERSPECTIVES IN DIABETES Challenging the FDA Black Box Warning for High Aspirin Dose With Ticagrelor in Patients With Diabetes James J. DiNicolantonio and Victor L. Serebruany – Ticagrelor, a novel reversible antiplatelet agent, has a Food and ASA 300 325 mg (53.6%) in the U.S. compared with the Drug Administration (FDA) black box warning to avoid mainte- rest of the world (1.7%) was the only factor to explain nance doses of aspirin (ASA) .100 mg/daily. This restriction is (out of 37 variables explored) the regional interaction based on the hypothesis that ASA doses .100 mg somehow de- that ticagrelor was less effective and potentially more creased ticagrelor’s benefit in the Platelet Inhibition and Patient harmful than clopidogrel (2). However, this interaction Outcomes (PLATO) U.S. cohort. However, these data are highly was not significant, is highly postrandomized, comes postrandomized, come from a very small subgroup in PLATO from a very small subgroup of PLATO, and makes no (57% of patients in the U.S. site), and make no biological sense. biological sense (3). Moreover, the ticagrelor-ASA interaction was not significant by any multivariate Cox regression analyses. The Complete Re- sponse Review for ticagrelor indicates that for U.S. PLATO patients, an ASA dose .300 mg was not a significant interaction TICAGRELOR-ASA HYPOTHESIS for vascular outcomes. In the ticagrelor-ASA .300 mg cohort, all- The claimed ticagrelor-ASA interaction states that ticagrelor cause and vascular mortality were not significantly increased fi – P plus low-dose ASA is bene cial, whereas increasing doses (hazard ratio [HR] 1.27 [95% CI 0.84 1.93], = 0.262 and 1.39 of ASA in combination with ticagrelor produces adverse [0.87–2.2], P = 0.170), respectively.
    [Show full text]
  • GTH 2021 State of the Art—Cardiac Surgery: the Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery
    Review Article 59 GTH 2021 State of the Art—Cardiac Surgery: The Perioperative Management of Heparin-Induced Thrombocytopenia in Cardiac Surgery Laura Ranta1 Emmanuelle Scala1 1 Department of Anesthesiology, Cardiothoracic and Vascular Address for correspondence Emmanuelle Scala, MD, Centre Anesthesia, Lausanne University Hospital (CHUV), Lausanne, Hospitalier Universitaire Vaudois, Rue du Bugnon 46, BH 05/300, 1011 Switzerland Lausanne, Suisse, Switzerland (e-mail: [email protected]). Hämostaseologie 2021;41:59–62. Abstract Heparin-induced thrombocytopenia (HIT) is a severe, immune-mediated, adverse drug Keywords reaction that paradoxically induces a prothrombotic state. Particularly in the setting of ► Heparin-induced cardiac surgery, where full anticoagulation is required during cardiopulmonary bypass, thrombocytopenia the management of HIT can be highly challenging, and requires a multidisciplinary ► cardiac surgery approach. In this short review, the different perioperative strategies to run cardiopul- ► state of the art monary bypass will be summarized. Introduction genicity of the antibodies and is diagnostic for HIT. The administration of heparin to a patient with circulating Heparin-induced thrombocytopenia (HIT) is a severe, im- pathogenic HITabs puts the patient at immediate risk of mune-mediated, adverse drug reaction that paradoxically severe thrombotic complications. induces a prothrombotic state.1,2 Particularly in the setting The time course of HIT can be divided into four distinct of cardiac surgery, where full anticoagulation is required phases.6 Acute HIT is characterized by thrombocytopenia during cardiopulmonary bypass (CPB), the management of and/or thrombosis, the presence of HITabs, and confirma- HIT can be highly challenging, and requires a multidisciplin- tion of their platelet activating capacity by a functional ary approach.
    [Show full text]
  • Inverse Agonism of SQ 29,548 and Ramatroban on Thromboxane A2 Receptor
    Inverse Agonism of SQ 29,548 and Ramatroban on Thromboxane A2 Receptor Raja Chakraborty1,3, Rajinder P. Bhullar1, Shyamala Dakshinamurti2,3, John Hwa4, Prashen Chelikani1,2,3* 1 Department of Oral Biology, University of Manitoba, Winnipeg, Manitoba, Canada, 2 Departments of Pediatrics, Physiology, University of Manitoba, Winnipeg, Manitoba, Canada, 3 Biology of Breathing Group- Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada, 4 Department of Internal Medicine (Cardiology), Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, United States of America Abstract G protein-coupled receptors (GPCRs) show some level of basal activity even in the absence of an agonist, a phenomenon referred to as constitutive activity. Such constitutive activity in GPCRs is known to have important pathophysiological roles in human disease. The thromboxane A2 receptor (TP) is a GPCR that promotes thrombosis in response to binding of the prostanoid, thromboxane A2. TP dysfunction is widely implicated in pathophysiological conditions such as bleeding disorders, hypertension and cardiovascular disease. Recently, we reported the characterization of a few constitutively active mutants (CAMs) in TP, including a genetic variant A160T. Using these CAMs as reporters, we now test the inverse agonist properties of known antagonists of TP, SQ 29,548, Ramatroban, L-670596 and Diclofenac, in HEK293T cells. Interestingly, SQ 29,548 reduced the basal activity of both, WT-TP and the CAMs while Ramatroban was able to reduce the basal activity of only the CAMs. Diclofenac and L-670596 showed no statistically significant reduction in basal activity of WT-TP or CAMs. To investigate the role of these compounds on human platelet function, we tested their effects on human megakaryocyte based system for platelet activation.
    [Show full text]
  • Effect of Prostanoids on Human Platelet Function: an Overview
    International Journal of Molecular Sciences Review Effect of Prostanoids on Human Platelet Function: An Overview Steffen Braune, Jan-Heiner Küpper and Friedrich Jung * Institute of Biotechnology, Molecular Cell Biology, Brandenburg University of Technology, 01968 Senftenberg, Germany; steff[email protected] (S.B.); [email protected] (J.-H.K.) * Correspondence: [email protected] Received: 23 October 2020; Accepted: 23 November 2020; Published: 27 November 2020 Abstract: Prostanoids are bioactive lipid mediators and take part in many physiological and pathophysiological processes in practically every organ, tissue and cell, including the vascular, renal, gastrointestinal and reproductive systems. In this review, we focus on their influence on platelets, which are key elements in thrombosis and hemostasis. The function of platelets is influenced by mediators in the blood and the vascular wall. Activated platelets aggregate and release bioactive substances, thereby activating further neighbored platelets, which finally can lead to the formation of thrombi. Prostanoids regulate the function of blood platelets by both activating or inhibiting and so are involved in hemostasis. Each prostanoid has a unique activity profile and, thus, a specific profile of action. This article reviews the effects of the following prostanoids: prostaglandin-D2 (PGD2), prostaglandin-E1, -E2 and E3 (PGE1, PGE2, PGE3), prostaglandin F2α (PGF2α), prostacyclin (PGI2) and thromboxane-A2 (TXA2) on platelet activation and aggregation via their respective receptors. Keywords: prostacyclin; thromboxane; prostaglandin; platelets 1. Introduction Hemostasis is a complex process that requires the interplay of multiple physiological pathways. Cellular and molecular mechanisms interact to stop bleedings of injured blood vessels or to seal denuded sub-endothelium with localized clot formation (Figure1).
    [Show full text]
  • Activation of the Murine EP3 Receptor for PGE2 Inhibits Camp Production and Promotes Platelet Aggregation
    Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation Jean-Etienne Fabre, … , Thomas M. Coffman, Beverly H. Koller J Clin Invest. 2001;107(5):603-610. https://doi.org/10.1172/JCI10881. Article The importance of arachidonic acid metabolites (termed eicosanoids), particularly those derived from the COX-1 and COX-2 pathways (termed prostanoids), in platelet homeostasis has long been recognized. Thromboxane is a potent agonist, whereas prostacyclin is an inhibitor of platelet aggregation. In contrast, the effect of prostaglandin E2 (PGE2) on platelet aggregation varies significantly depending on its concentration. Low concentrations of PGE2 enhance platelet aggregation, whereas high PGE2 levels inhibit aggregation. The mechanism for this dual action of PGE2 is not clear. This study shows that among the four PGE2 receptors (EP1–EP4), activation of EP3 is sufficient to mediate the proaggregatory actions of low PGE2 concentration. In contrast, the prostacyclin receptor (IP) mediates the inhibitory effect of higher PGE2 concentrations. Furthermore, the relative activation of these two receptors, EP3 and IP, regulates the intracellular level of cAMP and in this way conditions the response of the platelet to aggregating agents. Consistent with these findings, loss of the EP3 receptor in a model of venous inflammation protects against formation of intravascular clots. Our results suggest that local production of PGE2 during an inflammatory process can modulate ensuing platelet responses. Find the latest version: https://jci.me/10881/pdf Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation Jean-Etienne Fabre,1 MyTrang Nguyen,1 Krairek Athirakul,2 Kenneth Coggins,1 John D.
    [Show full text]
  • Prostacyclin Therapies for the Treatment of Pulmonary Arterial Hypertension
    Eur Respir J 2008; 31: 891–901 DOI: 10.1183/09031936.00097107 CopyrightßERS Journals Ltd 2008 SERIES ‘‘PULMONARY HYPERTENSION: BASIC CONCEPTS FOR PRACTICAL MANAGEMENT’’ Edited by M.M. Hoeper and A.T. Dinh-Xuan Number 2 in this Series Prostacyclin therapies for the treatment of pulmonary arterial hypertension M. Gomberg-Maitland* and H. Olschewski# ABSTRACT: Prostacyclin and its analogues (prostanoids) are potent vasodilators and possess AFFILIATIONS antithrombotic, antiproliferative and anti-inflammatory properties. Pulmonary hypertension (PH) *Dept of Cardiology, University of Chicago Hospitals, Chicago, IL, USA. is associated with vasoconstriction, thrombosis and proliferation, and the lack of endogenous #Dept of Pulmonology, Medical prostacyclin may considerably contribute to this condition. This supports a strong rationale for University Graz, Graz, Austria. prostanoid use as therapy for this disease. The first experiences of prostanoid therapy in PH patients were published in 1980. CORRESPONDENCE H. Olschewski Epoprostenol, a synthetic analogue of prostacyclin, and the chemically stable analogues Dept of Pulmonology iloprost, beraprost and treprostinil were tested in randomised controlled trials. The biological Medical University Graz actions are mainly mediated by activation of specific receptors of the target cells; however, new Auenbruggerplatz 20 data suggest effects on additional intracellular pathways. In the USA and some European Graz 8010 Austria countries, intravenous infusion of epoprostenol and treprostinil, as well as subcutaneous infusion Fax: 43 3163853578 of treprostinil and inhalation of iloprost, have been approved for therapy of pulmonary arterial E-mail: horst.olschewski@ hypertension. Iloprost infusion and beraprost tablets have been approved in few other countries. meduni-graz.at Ongoing clinical studies investigate oral treprostinil, inhaled treprostinil and the combination of Received: inhaled iloprost and sildenafil in pulmonary arterial hypertension.
    [Show full text]
  • HIGHLIGHTS of PRESCRIBING INFORMATION These Highlights Do Not Include All the Information Needed to Use Remodulin Safely and Effectively
    HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Remodulin safely and effectively. See full prescribing information for Remodulin. ---------------------DOSAGE FORMS AND STRENGTHS---------------------- • Remodulin is supplied in 20 mL vials containing 20, 50, 100, or 200 mg REMODULIN (treprostinil) Injection of treprostinil (1 mg/mL, 2.5 mg/mL, 5 mg/mL or 10 mg/mL). (3) Initial U.S. Approval: May 2002 -------------------------------CONTRAINDICATIONS------------------------------ ----------------------------RECENT MAJOR CHANGES-------------------------- None Dosage and Administration (2.1) 01/2010 -----------------------WARNINGS AND PRECAUTIONS------------------------ Warnings and Precautions (5.1) 01/2010 • Chronic intravenous infusions of Remodulin are delivered using an ----------------------------INDICATIONS AND USAGE--------------------------- indwelling central venous catheter. This route is associated with the risk Remodulin is a prostacyclin vasodilator indicated for: of blood stream infections (BSIs) and sepsis, which may be fatal. (5.1) • • Treatment of pulmonary arterial hypertension (PAH) in patients with Remodulin should be used only by clinicians experienced in the NYHA Class II-IV symptoms, to diminish symptoms associated with diagnosis and treatment of PAH. (5.2) exercise (1.1) • Adjust dosage based on clinical response, including infusion site • Patients who require transition from Flolan, to reduce the rate of clinical symptoms. (5.3) deterioration. The risks and benefits
    [Show full text]
  • Increased Serum Thromboxane A2 and Prostacyclin but Lower Complement C3 and C4
    medRxiv preprint doi: https://doi.org/10.1101/2021.04.10.21255240; this version posted April 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . 1 Increased serum thromboxane A2 and prostacyclin but lower complement C3 and C4 levels in COVID-19: associations with chest CT-scan anomalies and lowered peripheral oxygen saturation. Hussein Kadhem Al-Hakeim a, Shaymaa Ali Al-Hamami, b, Michael Maes c, d, e. a Department of Chemistry, College of Science, University of Kufa, Iraq. E-mail: [email protected] b Department of Medical Laboratory Techniques, Altoosi University College, Najaf, Iraq. E-mail: [email protected] c Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria. d Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. e School of Medicine, IMPACT Strategic Research Centre, Deakin University, PO Box 281, Geelong, VIC, 3220, Australia. Corresponding author: Prof. Dr. Michael Maes, M.D., Ph.D., IMPACT Strategic Research Center, Barwon Health, Deakin University, Geelong, Vic, Australia. E-mail: [email protected]. 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.04.10.21255240; this version posted April 13, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Prostacyclin Synthesis by COX-2 Endothelial Cells
    Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-2 This information is current as of October 2, 2021. Gillian E. Caughey, Leslie G. Cleland, Peter S. Penglis, Jennifer R. Gamble and Michael J. James J Immunol 2001; 167:2831-2838; ; doi: 10.4049/jimmunol.167.5.2831 http://www.jimmunol.org/content/167/5/2831 Downloaded from References This article cites 36 articles, 23 of which you can access for free at: http://www.jimmunol.org/content/167/5/2831.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Roles of Cyclooxygenase (COX)-1 and COX-2 in Prostanoid Production by Human Endothelial Cells: Selective Up-Regulation of Prostacyclin Synthesis by COX-21 Gillian E. Caughey,2* Leslie G.
    [Show full text]
  • 2621.Full.Pdf
    Prostaglandin D2 Plays an Essential Role in Chronic Allergic Inflammation of the Skin via CRTH2 Receptor This information is current as Takahiro Satoh, Rie Moroi, Kosuke Aritake, Yoshihiro of September 29, 2021. Urade, Yasumasa Kanai, Koji Sumi, Hiroo Yokozeki, Hiroyuki Hirai, Kinya Nagata, Toshifumi Hara, Masanori Utsuyama, Katsuiku Hirokawa, Kazuo Sugamura, Kiyoshi Nishioka and Masataka Nakamura J Immunol 2006; 177:2621-2629; ; Downloaded from doi: 10.4049/jimmunol.177.4.2621 http://www.jimmunol.org/content/177/4/2621 References This article cites 36 articles, 13 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/177/4/2621.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 29, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2006 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online
    [Show full text]
  • Recent Advances in Targeting the Prostacyclin Pathway in Pulmonary Arterial Hypertension
    REVIEW PULMONARY HYPERTENSION Recent advances in targeting the prostacyclin pathway in pulmonary arterial hypertension Irene M. Lang1 and Sean P. Gaine2 Affiliations: 1Division of Cardiology, Medical University of Vienna, Vienna, Austria. 2National Pulmonary Hypertension Unit, Mater Misericordiae University Hospital, Dublin, Ireland. Correspondence: Irene M. Lang, Division of Cardiology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria. E-mail: [email protected] ABSTRACT Pulmonary arterial hypertension (PAH) is a severe disease characterised by increased pulmonary vascular resistance, which leads to restricted pulmonary arterial blood flow and elevated pulmonary arterial pressure. In patients with PAH, pulmonary concentrations of prostacyclin, a prostanoid that targets several receptors including the IP prostacyclin receptor, are reduced. To redress this balance, epoprostenol, a synthetic prostacyclin, or analogues of prostacyclin have been given therapeutically. These therapies improve exercise capacity, functional class and haemodynamic parameters. In addition, epoprostenol improves survival among patients with PAH. Despite their therapeutic benefits, treatments that target the prostacyclin pathway are underused. One key factor is their requirement for parenteral administration: continuous intravenous administration can lead to embolism and thrombosis; subcutaneous administration is associated with infusion-site pain; and inhalation is time consuming, requiring multiple daily administrations. Nevertheless,
    [Show full text]